Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) rose 37.9% on Thursday . The stock traded as high as C$0.24 and last traded at C$0.20. Approximately 1,160,600 shares traded hands during mid-day trading, an increase of 120% from the average daily volume of 528,233 shares. The stock had previously closed at C$0.15.
Hemostemix Price Performance
The firm has a market capitalization of C$20.91 million, a P/E ratio of -12.00 and a beta of 0.20. The firm’s fifty day moving average price is C$0.09 and its 200-day moving average price is C$0.07.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
See Also
- Five stocks we like better than Hemostemix
- Ride Out The Recession With These Dividend Kings
- 3 Natural Gas Stocks Set to Thrive in This Winter’s Freeze
- How to buy stock: A step-by-step guide for beginners
- Bullish on Athleisure? Here’s Why Lululemon Stock Shines
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- MarketBeat Week in Review – 01/06 – 01/10
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
